7/23/2012 10:08:29 AM
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. (IBS) and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware. In its counterclaims, Illumina has sued IBS and Qiagen for infringement of three Illumina patents, entitled “Labelled Nucleotides.” These three patents (U.S. Patent Nos. 7,057,026; 7,785,796; and 8,158,346, all expiring in December 2022), are applicable to the sequencing by synthesis technology being used in the IBS Max-Seq and MINI-20 DNA Sequencers. Illumina is seeking all available remedies, including injunctive relief. With respect to the claims brought by Columbia and IBS, Illumina has denied all of Columbia’s and IBS’s allegations of patent infringement, and has asserted that Columbia’s patents are invalid.
comments powered by